Hakan Demirci1, Leslie M Niziol2, Zeynep Ozkurt2, Naziha Slimani2, Cem Ozgonul2, Tiffany Liu3, David C Musch4, Miguel Materin3. 1. Ocular Oncology, Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA. Electronic address: hdemirci@med.umich.edu. 2. Ocular Oncology, Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA. 3. Department of Ophthalmology and Visual Sciences, Yale University, New Haven, Connecticut, USA. 4. Ocular Oncology, Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA; Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
PURPOSE: To evaluate the prognostication of choroidal melanoma (CM) by the gene expression profiling (GEP) test. DESIGN: Cohort study. METHODS: Retrospective review of 293 CM patients from 2 centers. RESULTS: Of 293 patients, 132 (45%) were class 1A by GEP, 63 (22%) were class 1B, and 98 (33%) were class 2. Class 2 tumors had more ciliary body involvement and greater largest basal dimension (LBD), and were thicker. GEP results and increasing LBD were independently predictive of time to metastasis. Kaplan-Meier survival analysis estimated the probability of 3-year metastasis-free survival (MFS) of 0.99 in class 1A, 0.90 in class 1B, and 0.60 in class 2. The probability of 3-year MFS was 0.49 in class 2 patients with LBD ≥ 12 mm vs 1.00 in those with LBD < 12 mm, 0.89 in class 1B with LBD ≥ 12 mm vs 0.93 in those with LBD < 12 mm, and 0.99 in class 1A with LBD ≥ 12 mm vs 1.00 in those with LBD < 12 mm. In American Joint Committee on Cancer (AJCC) stage I CMs, the probability of 3-year MFS was 1.0 for class 1A and 1B, and 0.79 for class 2. In stage II CMs, the probability of 3-year MFS was 0.99 for class 1A, 0.89 for class 1B, and 0.61 for class 2. In stage III CM, the probability of 3-year MFS was 1.0 for class 1A, 0.60 for class 1B, and 0.41 for class 2. CONCLUSIONS: GEP testing provided significant prognostic information for CM. Class 2 tumors with LBD ≥ 12 mm and class 2 and 1B tumors with AJCC stage III showed significantly worse prognosis.
PURPOSE: To evaluate the prognostication of choroidal melanoma (CM) by the gene expression profiling (GEP) test. DESIGN: Cohort study. METHODS: Retrospective review of 293 CMpatients from 2 centers. RESULTS: Of 293 patients, 132 (45%) were class 1A by GEP, 63 (22%) were class 1B, and 98 (33%) were class 2. Class 2 tumors had more ciliary body involvement and greater largest basal dimension (LBD), and were thicker. GEP results and increasing LBD were independently predictive of time to metastasis. Kaplan-Meier survival analysis estimated the probability of 3-year metastasis-free survival (MFS) of 0.99 in class 1A, 0.90 in class 1B, and 0.60 in class 2. The probability of 3-year MFS was 0.49 in class 2 patients with LBD ≥ 12 mm vs 1.00 in those with LBD < 12 mm, 0.89 in class 1B with LBD ≥ 12 mm vs 0.93 in those with LBD < 12 mm, and 0.99 in class 1A with LBD ≥ 12 mm vs 1.00 in those with LBD < 12 mm. In American Joint Committee on Cancer (AJCC) stage I CMs, the probability of 3-year MFS was 1.0 for class 1A and 1B, and 0.79 for class 2. In stage II CMs, the probability of 3-year MFS was 0.99 for class 1A, 0.89 for class 1B, and 0.61 for class 2. In stage III CM, the probability of 3-year MFS was 1.0 for class 1A, 0.60 for class 1B, and 0.41 for class 2. CONCLUSIONS: GEP testing provided significant prognostic information for CM. Class 2 tumors with LBD ≥ 12 mm and class 2 and 1B tumors with AJCC stage III showed significantly worse prognosis.
Authors: Thomas M Aaberg; Kyle R Covington; Tony Tsai; Yevgeniy Shildkrot; Kristen M Plasseraud; Katherina M Alsina; Kristen M Oelschlager; Federico A Monzon Journal: Ocul Oncol Pathol Date: 2020-07-06
Authors: Wajiha J Kheir; Sandra S Stinnett; Sheridan Meltsner; Ekaterina Semenova; Yvonne M Mowery; Oana Craciunescu; David G Kirsch; Miguel A Materin Journal: Adv Radiat Oncol Date: 2022-01-14
Authors: Basil K Williams; Jennifer J Siegel; Katherina M Alsina; Lauren Johnston; Amanda Sisco; Kyleigh LiPira; Sara M Selig; Peter G Hovland Journal: Melanoma Manag Date: 2022-09-16